title: [Priority for atypical antipsychotics--comments on the article by Dose M. Priority for Atypicals? Current studies clarify some aspects. Psychiat Prax 2007; 34:46-49].
authors.affiliation: juergen.fritze@dgn.de
authors.forename: Jürgen
authors.initials: J
authors.lastname: Fritze
authors.forename: Josef
authors.initials: J
authors.lastname: Aldenhoff
authors.forename: Frank
authors.initials: F
authors.lastname: Bergmann
authors.forename: Gabriel
authors.initials: G
authors.lastname: Eckermann
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Maier
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Gaebel
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D015982:Bias; D003363:Cost Control; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005858:Germany; D006801:Humans; D009313:National Health Programs / Q000191:economics; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000191:economics; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents